Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation

Bone Marrow Transplantation

Volumn 37, Issue 5, 2006, Pages 511-515

  Lee, C K ^a,b   Zangari, M ^a   Fassas, A ^a   Thertulien, R ^a   Talamo, G ^a   Badros, A ^a   Cottler Fox, M ^a   van Rhee, F ^a   Barlogie, B ^a   Tricot, G ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Allogeneic transplantation; Cytogenetic abnormalities; Multiple myeloma

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; COTRIMOXAZOLE; CYCLOSPORIN; FLUDARABINE; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; MELPHALAN; METHYLPREDNISOLONE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME ABERRATION; CORRELATION ANALYSIS; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DIPLOIDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METAPHASE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; MYCOSIS; NONMYELOABLATIVE CONDITIONING; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RELAPSE; REMISSION; RISK ASSESSMENT; RISK REDUCTION; SIBLING; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; WHOLE BODY RADIATION;

ADULT; AGED; CHROMOSOME ABERRATIONS; CLONE CELLS; FEMALE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; METAPHASE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TUMOR ESCAPE;

EID: 33645306622     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705267     Document Type: Article

References (25)

1. Bensinger W, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol 2001; 38: 243-249.
2. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E et al. Treatment of multiple myeloma. Blood 2004; 103: 20-32.
3. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-216.
4. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood 2005; 105: 4532-4539.
5. Kroger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/ fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698-708.
6. Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003; 31: 73-80.
7. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-3924.
8. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
9. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression. Blood 2003; 101: 3849-3856.
10. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
11. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295-1303.
12. Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 1998; 92: 4269-4278.
13. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. JASA 1958; 53: 457-481.
15. Collett D. Modeling Survival Data in Medical Research. Chapman and Hall: London, 1994.
16. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362-4364.
17. Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect. Blood 2001; 98: 934-939.
18. Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 2002; 8: 1433-1437.
19. Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2001; 97: 2886-2895.
20. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Research 2004; 64: 1546-1558.
21. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
22. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229-2238.
23. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041-1047.
24. Kroger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A et al. Deletion of chromosome band 13q14 detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose reduced stem cell transplantation. Blood 2004; 103: 4056-4061.
25. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-4062.